Trials / Completed
CompletedNCT00123851
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (planned)
- Sponsor
- Dana-Farber Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is designed to investigate the safety, tolerability and the effectiveness when OSI-774 (tarceva) is combined with oxaliplatin and capecitabine in treating patients with metastatic colorectal cancer.
Detailed description
Patients will be treated with OSI-774 (orally) daily, oxaliplatin (intravenously) every 3 weeks, and capecitabine (orally) twice daily for 14 days followed by a 7-day rest period. This will constitute a 21-day treatment cycle. Treatment will continue until disease progression or unacceptable toxicity occurs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarceva (OSI-774) | |
| DRUG | Capecitabine | |
| DRUG | Oxaliplatin |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-07-26
- Last updated
- 2009-04-28
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00123851. Inclusion in this directory is not an endorsement.